OPKO HEALTH, INC.
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
About Opko Health
Pharmaceutical Preparations, SIC 2834
OPKO Health is a healthcare enterprise that operates primarily through two main business segments: diagnostics and pharmaceuticals. Within its diagnostics division, the company provides diagnostic laboratory testing services and diagnostic products. Through its pharmaceutical division, the business develops, manufactures, and distributes pharmaceutical treatments and therapeutic compounds, including Rayaldee. The organization delivers its healthcare products and laboratory services to a diverse customer base that includes individual patients, commercial healthcare insurers, institutional client payers, and government healthcare programs such as Medicare and Medicaid.
The enterprise conducts its commercial, developmental, and operational activities across multiple international regions. Geographically, its operations and affiliate entities span several countries, which include the United States, Mexico, Spain, Chile, Ireland, Israel, and Luxembourg. In the United States, its documented activities and facilities include a presence in New York and Connecticut. The provided records detail operations and business units in these territories without specifying a corporate headquarters.
Summary of the business section of Opko Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- OPKO HEALTH, INC.
- Headquarters
- Miami, FL
- Address
- 4400 Biscayne Blvd. 33137
- Phone
- (305) 575-4181
- Employees
- 2,275, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Miami, Florida
Stock & identifiers
- Ticker
- OPK
- Exchange
- Nasdaq
- Shares outstanding
- 746M, Jul 17, 2026
- Public float
- $539.51M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 944809
- CUSIP
- 68375N103
- ISIN
- US68375N1037
- LEI
- 529900A4S2D4OGOJLL02
- EIN
- 75-2402409
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Steven D. Rubin | Executive VP-Administration, Director | 26,663,028 |
| Phillip Md Et Al Frost | CEO & Chairman, Director | 248,082,576 |
| Gary J. Nabel | Chief Innovation Officer, Director | 20,833,727 |
| Elias A. Zerhouni | Vice Chairman and President, Director | 20,367,114 |
| Jane Ph D. Hsiao | Vice Chairman & CTO, Director | 33,627,284 |
| Adam Logal | Sr. Vice President, CFO | 563,396 |
| Roger Medel Md | Director | – |
| Subbarao V. Uppaluri | Director | 3,158,817 |
| Richard C. Pfenniger Jr | Director | 325,000 |
| Alice Lin-Tsing Yu | Director | 66,490 |
| John A. Paganelli | Director | 403,515 |
| Prem A. Lachman | Director | 0 |
| Richard M. Krasno | Director | 103,333 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Phillip Frost | $1.85M | $1.34M | $1.66M | $32 | $125 |
| FY2024 Dr. Phillip Frost | $2.16M | $2.02M | $1.95M | $37 | $93 |
| FY2023 Dr. Phillip Frost | $2.28M | $2.17M | $2.03M | $38 | $94 |
| FY2022 Dr. Phillip Frost | $972.20K | -$1.25M | $803.00K | $32 | $90 |
| FY2021 Dr. Phillip Frost | $2.10M | $2.40M | $2.30M | $122 | $100 |
| FY2020 | $1.54M | $3.33M | $1.95M | $269 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 2,275 full-time employees worldwide.”
Corporate history
Events identified from SEC filings